Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
Trump Family Files $10 Billion Lawsuit Over IRS Tax Disclosure 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
Novo Nordisk Launches Once-Daily Wegovy Pill in U.S. at Competitive Pricing 
Faith Leaders Arrested on Capitol Hill During Protest Against Trump Immigration Policies and ICE Funding 
Trump Extends AGOA Trade Program for Africa Through 2026, Supporting Jobs and U.S.-Africa Trade 
Trump Signs “America First Arms Transfer Strategy” to Prioritize U.S. Weapons Sales 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
U.S. Justice Department Removes DHS Lawyer After Blunt Remarks in Minnesota Immigration Court 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Paul Atkins Emphasizes Global Regulatory Cooperation at Fintech Conference 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
U.S. Health Secretary Robert F. Kennedy Jr. has reshaped national autism policy by appointing an entirely new slate of 21 members to the Interagency Autism Coordinating Committee (IACC), a federal panel that provides guidance on autism research and funding. The move has ignited sharp criticism from autism experts, scientists, and former committee members, due to several appointees’ ties to groups that promote unproven claims linking vaccines to autism.
Kennedy, a longtime critic of vaccines who has repeatedly claimed they are unsafe and associated with autism, said the newly appointed committee members bring decades of experience and will help deliver “the answers Americans deserve.” However, many in the medical and scientific community argue the changes could undermine evidence-based autism research and public trust in health policy.
The IACC, established in 2006, plays a key advisory role in shaping federal autism research priorities, influencing approximately $2 billion in annual funding. Historically, the committee included a balance of autism researchers, clinicians, self-advocates, parents, and government officials. In contrast, Kennedy replaced all prior members, breaking with past practice where some experts typically remained on the panel.
Among the new appointees are Daniel Rossignol, who has promoted discredited autism treatments such as chelation therapy, and John Gilmore, co-founder of the Autism Action Network, who has publicly linked his son’s autism to vaccination. Other members include Brownstone Institute fellow Toby Rogers and Autism Health founder Tracy Slepcevic, both associated with alternative autism treatment advocacy.
Autism Science Foundation President Alison Singer, who served on the committee for 12 years, warned the overhaul would harm people with autism and their families. Dr. Helen Tager-Flusberg of Boston University noted that many new members represent organizations advocating non-mainstream treatments, raising concerns that autism funding priorities could shift away from established science.
Kennedy has labeled rising autism rates—now estimated at one in 31 U.S. children by age eight—as an epidemic and has pledged to uncover causes and cures. He has also supported controversial positions, including promoting leucovorin as a treatment and raising alarms about Tylenol use during pregnancy, claims that health experts say lack strong scientific evidence.
